Special Issue "Botulinum Toxin Treatment for Spasticity and Pain"
Deadline for manuscript submissions: 30 November 2021.
Interests: rehabilitation; brain injury; stroke; spasticity; critical illness polyneuropathy; acquired severe brain injury; outcome
Spasticity is a troublesome disorder that may occur in subjects after central nervous system (CNS) damage following stroke, brain injury, spinal cord injury, multiple sclerosis, and cerebral palsy. Likewise, pain may be a challenging complaint in several diseases that affect the nervous system and may be coexistent with spasticity.
Spasticity can hamper the rehabilitation process and contributes to the loss of motor dexterity and ability by promoting pain, persistent abnormal postures, articular limitations, and muscular–tendon contractures. Pain and spasticity, if untreated, can lead to discomfort, decreased functioning and participation, and poor self-esteem and quality of life.
Although several pharmacological and not pharmacological treatments have been used in managing spasticity, botulinum toxin (BoNT) is the first line of therapy in focal spasticity. However, several questions remain unclear that encompass pathophysiological mechanisms (peripheral and central), modality of administration, site (single or multiple levels), dilution, severity of spasticity and dosage (high dosage), adjunct tools (cast, exercises, electrical stimulation), and the effect on functional recovery.
Therapies in treating pain and neuropathic pain may be poorly effective. BoNT has been proposed as a promising and efficacious therapeutic strategy, but likewise and even more so than spasticity treatment, many questions and issues remain unsolved.
This Special Issue will focus the role of BoNT in the management of spasticity and pain, addressing unclear questions and new approaches.
Dr. Domenico Intiso
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- botulinum toxin
- therapeutic strategies
- nervous system